How patient organizations are advancing healthcare in Africa</a> | March 2024</strong><br /> Source: <a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/">World Economic Forum</a><br /> Patient organisations are valuable for policymakers as they understand their community and the challenges they face best. As Africa&rsquo;s population grows to 2.5 billion by 2050, patient organisations will be essential for all Africans. </p> <p>&nbsp;</p> <p> <strong><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/d8556b921c324f26830284dfe651161d.ashx">Boosting healthcare capacity with AI</a> | January 2024</strong><br /> Source: <a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/">World Economic Forum</a><br /> Our populations' future health will dramatically change in high-, middle- and low-income countries. Learn how Artificial Intelligence (AI) can help healthcare systems cope with increasing stress and avoid waste in healthcare expenditure. </p> <p>&nbsp;</p> <p><strong><strong><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/b17487cca92e4e8ba626fb61aa592825.ashx">Nine for 2024, Pt 2: Phase change and the challenges of scale</a> </strong> | January 2024</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> The first of two articles on trends in the pharma and life sciences industries to watch out for in 2024. This part examines the trends that will reshape pharmaceutical markets and healthcare provision at scale in 2024 and beyond. </p> <p>&nbsp;</p> <p><strong><strong><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/70c297ca5f224461b984a721ae2fb6cd.ashx">Antimicrobial resistance: Avoiding antibiotic overconsumption with the right data</a></strong> | January 2024</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> Antimicrobial resistance, rendering antibiotics ineffective, is incredibly harmful, associated with 4.95 million deaths in 2019. The article discusses how to navigate the complex causes of the AMR challenge, and how to foster innovation of new treatments.</p> <p>&nbsp;</p> <p><strong><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/90f9acd71cc54ee2b72ae2145d257880.ashx">Collaborative sustainability by all, for all</strong></a> | January 2024</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.cphi-online.com/" target="_blank">CPHI Online</a><br /> CPHI Online has released its 2024 Pharma Trends Outlook report, in which Thought Leadership&rsquo;s Aurelio Arias contributed to an article on sustainability. The article considers how ESG topics will remain important for pharma in 2024, and discusses the volume of carbon emissions from pharma.</p> <p>&nbsp;</p> <p><strong><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/e36b28627606416fb1b38c664f39030f.ashx">Nine for 2024, Pt. 1: From fragility to resilience</strong></a> | December 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> The first of two articles on trends in the pharma and life sciences industries to watch out for in 2024. This part covers how pharma companies and healthcare systems can address issues of fragility by looking at emerging markets, supply chains, and addressing the healthcare capacity gap. </p> <p>&nbsp;</p> <p><strong><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/31f964d6cc914a98b6afe38e141d0c89.ashx">Pro Take: Making Medicines Greener </strong></a> | October 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.wsj.com/pro/sustainable-business" target="_blank">WSJ Sustainable Business</a><br /> Making and supplying medicines generates roughly a third of the global healthcare industry&rsquo;s greenhouse-gas emissions. Pharmaceutical companies committed to lowering their carbon footprint say the main challenges arise from their scope 3 emissions. The article covers how pharma companies can reduce their emissions from these sources. </p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/83c51aa562b647db8679698e8ff1b385.ashx">Microbiome therapeutics could be the next big thing in pharma</strong></a><strong> | June 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.healthcare-brew.com/" target="_blank">Healthcare Brew</a><br /> The microbiome-based therapeutic market is expected to be worth $1.6 billion by 2026. Interest in this field is growing, especially with two drugs targeting the microbiome being approved in the past year. What is the outlook for the microbiome?</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/6a765e4c0d804586a4102e3227660788.ashx">Nine for 2023, part one: a reflection on inflection</strong></a><strong> | January 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> The first in a 3-part series on what trends will be affecting the pharma and life sciences industries in the upcoming year. This first part focuses on global healthcare environmental challenges and what they mean for the pharmaceutical industry.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/dbe44b6426d844aeb55c46450cde4a5a.ashx">Nine for 2023, part two: healthcare&rsquo;s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms</strong></a><strong> | January 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> This second part of the 3-part series focuses on opportunities for pharma; the unmet need which lies at the heart of better healthcare provision, Point of Care Diagnostics and new pharmacotherapy classes becoming commercially available in 2023.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/5b421c7a8561493a9c43f7dfcb84bc07.ashx">Nine for 2023, part three: surviving or thriving?</strong></a><strong> | January 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> This final part of the 3-part series concerns issues that will change the direction of healthcare and the pharmaceutical industry this year, with three key competitive issues for pharmaceutical companies in 2023 being assessed.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/2680731baf78447b944295d00dc7a77f.ashx">3 ways healthcare systems can reduce their carbon footprint</strong></a><strong> | November 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> Rapid climate change has a direct impact on human health. The risk to human health bears down heavily upon healthcare systems. What can be done by these systems to reduce their carbon emissions?</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/33cd80cb8e4940dca84807830911ab39.ashx">&ldquo;Your order has been dispatched&rdquo;: Moving patient care closer to the home</strong></a><strong> | October 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://medhealthoutlook.com/" target="_blank">Medhealth Outlook</a><br /> Healthcare has increasingly moved towards treating patients at an individual level. As part of this phenomena there is a growing focus on providing patients greater flexibility on the location and timing of how they receive care. Learn how pharma and others can success during this change.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/6cff485c798644d1a0228ec9e0a44082.ashx">Is the launch environment really more competitive now?</strong></a><strong> | October 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> It&rsquo;s often stated - mostly without reference to data - that the environment for innovative launches is more competitive now than it ever has been. Is this true? We interrogate this claim using IQVIA&rsquo;s long term market data to analyse nearly 30 years of launches.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/de00d1622aba4ecf8df8bcfec48d018c.ashx">How can countries achieve digital maturity in healthcare?</strong></a><strong> | August 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> Healthcare systems are becoming increasingly digitised, but this trend has accelerated in the last 10 years, as well as been given a huge boost by the COVID-19 pandemic. Progression towards digital maturity is uneven between countries, but there are successful examples to follow.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/4cc5453e53f1430abc834161eaebfd10.ashx">How clinical development can tackle Africa's unique health needs</strong></a><strong> | May 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> By 2050, the United Nations projects that 25% of all humanity will be African, with non-communicable diseases poised to become the leading cause of deaths in sub-Saharan Africa. The poor level of commercially led clinical development activity in Africa must be addressed considering these changing factors.</p>" /> How patient organizations are advancing healthcare in Africa</a> | March 2024</strong><br /> Source: <a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/">World Economic Forum</a><br /> Patient organisations are valuable for policymakers as they understand their community and the challenges they face best. As Africa&rsquo;s population grows to 2.5 billion by 2050, patient organisations will be essential for all Africans. </p> <p>&nbsp;</p> <p> <strong><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/d8556b921c324f26830284dfe651161d.ashx">Boosting healthcare capacity with AI</a> | January 2024</strong><br /> Source: <a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/">World Economic Forum</a><br /> Our populations' future health will dramatically change in high-, middle- and low-income countries. Learn how Artificial Intelligence (AI) can help healthcare systems cope with increasing stress and avoid waste in healthcare expenditure. </p> <p>&nbsp;</p> <p><strong><strong><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/b17487cca92e4e8ba626fb61aa592825.ashx">Nine for 2024, Pt 2: Phase change and the challenges of scale</a> </strong> | January 2024</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> The first of two articles on trends in the pharma and life sciences industries to watch out for in 2024. This part examines the trends that will reshape pharmaceutical markets and healthcare provision at scale in 2024 and beyond. </p> <p>&nbsp;</p> <p><strong><strong><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/70c297ca5f224461b984a721ae2fb6cd.ashx">Antimicrobial resistance: Avoiding antibiotic overconsumption with the right data</a></strong> | January 2024</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> Antimicrobial resistance, rendering antibiotics ineffective, is incredibly harmful, associated with 4.95 million deaths in 2019. The article discusses how to navigate the complex causes of the AMR challenge, and how to foster innovation of new treatments.</p> <p>&nbsp;</p> <p><strong><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/90f9acd71cc54ee2b72ae2145d257880.ashx">Collaborative sustainability by all, for all</strong></a> | January 2024</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.cphi-online.com/" target="_blank">CPHI Online</a><br /> CPHI Online has released its 2024 Pharma Trends Outlook report, in which Thought Leadership&rsquo;s Aurelio Arias contributed to an article on sustainability. The article considers how ESG topics will remain important for pharma in 2024, and discusses the volume of carbon emissions from pharma.</p> <p>&nbsp;</p> <p><strong><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/e36b28627606416fb1b38c664f39030f.ashx">Nine for 2024, Pt. 1: From fragility to resilience</strong></a> | December 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> The first of two articles on trends in the pharma and life sciences industries to watch out for in 2024. This part covers how pharma companies and healthcare systems can address issues of fragility by looking at emerging markets, supply chains, and addressing the healthcare capacity gap. </p> <p>&nbsp;</p> <p><strong><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/31f964d6cc914a98b6afe38e141d0c89.ashx">Pro Take: Making Medicines Greener </strong></a> | October 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.wsj.com/pro/sustainable-business" target="_blank">WSJ Sustainable Business</a><br /> Making and supplying medicines generates roughly a third of the global healthcare industry&rsquo;s greenhouse-gas emissions. Pharmaceutical companies committed to lowering their carbon footprint say the main challenges arise from their scope 3 emissions. The article covers how pharma companies can reduce their emissions from these sources. </p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/83c51aa562b647db8679698e8ff1b385.ashx">Microbiome therapeutics could be the next big thing in pharma</strong></a><strong> | June 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.healthcare-brew.com/" target="_blank">Healthcare Brew</a><br /> The microbiome-based therapeutic market is expected to be worth $1.6 billion by 2026. Interest in this field is growing, especially with two drugs targeting the microbiome being approved in the past year. What is the outlook for the microbiome?</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/6a765e4c0d804586a4102e3227660788.ashx">Nine for 2023, part one: a reflection on inflection</strong></a><strong> | January 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> The first in a 3-part series on what trends will be affecting the pharma and life sciences industries in the upcoming year. This first part focuses on global healthcare environmental challenges and what they mean for the pharmaceutical industry.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/dbe44b6426d844aeb55c46450cde4a5a.ashx">Nine for 2023, part two: healthcare&rsquo;s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms</strong></a><strong> | January 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> This second part of the 3-part series focuses on opportunities for pharma; the unmet need which lies at the heart of better healthcare provision, Point of Care Diagnostics and new pharmacotherapy classes becoming commercially available in 2023.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/5b421c7a8561493a9c43f7dfcb84bc07.ashx">Nine for 2023, part three: surviving or thriving?</strong></a><strong> | January 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> This final part of the 3-part series concerns issues that will change the direction of healthcare and the pharmaceutical industry this year, with three key competitive issues for pharmaceutical companies in 2023 being assessed.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/2680731baf78447b944295d00dc7a77f.ashx">3 ways healthcare systems can reduce their carbon footprint</strong></a><strong> | November 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> Rapid climate change has a direct impact on human health. The risk to human health bears down heavily upon healthcare systems. What can be done by these systems to reduce their carbon emissions?</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/33cd80cb8e4940dca84807830911ab39.ashx">&ldquo;Your order has been dispatched&rdquo;: Moving patient care closer to the home</strong></a><strong> | October 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://medhealthoutlook.com/" target="_blank">Medhealth Outlook</a><br /> Healthcare has increasingly moved towards treating patients at an individual level. As part of this phenomena there is a growing focus on providing patients greater flexibility on the location and timing of how they receive care. Learn how pharma and others can success during this change.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/6cff485c798644d1a0228ec9e0a44082.ashx">Is the launch environment really more competitive now?</strong></a><strong> | October 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> It&rsquo;s often stated - mostly without reference to data - that the environment for innovative launches is more competitive now than it ever has been. Is this true? We interrogate this claim using IQVIA&rsquo;s long term market data to analyse nearly 30 years of launches.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/de00d1622aba4ecf8df8bcfec48d018c.ashx">How can countries achieve digital maturity in healthcare?</strong></a><strong> | August 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> Healthcare systems are becoming increasingly digitised, but this trend has accelerated in the last 10 years, as well as been given a huge boost by the COVID-19 pandemic. Progression towards digital maturity is uneven between countries, but there are successful examples to follow.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/4cc5453e53f1430abc834161eaebfd10.ashx">How clinical development can tackle Africa's unique health needs</strong></a><strong> | May 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> By 2050, the United Nations projects that 25% of all humanity will be African, with non-communicable diseases poised to become the leading cause of deaths in sub-Saharan Africa. The poor level of commercially led clinical development activity in Africa must be addressed considering these changing factors.</p>" />
Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/

EMEA Thought Leadership

Articles in the trade press

How patient organizations are advancing healthcare in Africa | March 2024
Source: World Economic Forum
Patient organisations are valuable for policymakers as they understand their community and the challenges they face best. As Africa’s population grows to 2.5 billion by 2050, patient organisations will be essential for all Africans.

 

Boosting healthcare capacity with AI | January 2024
Source: World Economic Forum
Our populations' future health will dramatically change in high-, middle- and low-income countries. Learn how Artificial Intelligence (AI) can help healthcare systems cope with increasing stress and avoid waste in healthcare expenditure.

 

Nine for 2024, Pt 2: Phase change and the challenges of scale | January 2024
Source: Pharmaphorum
The first of two articles on trends in the pharma and life sciences industries to watch out for in 2024. This part examines the trends that will reshape pharmaceutical markets and healthcare provision at scale in 2024 and beyond.

 

Antimicrobial resistance: Avoiding antibiotic overconsumption with the right data | January 2024
Source: World Economic Forum
Antimicrobial resistance, rendering antibiotics ineffective, is incredibly harmful, associated with 4.95 million deaths in 2019. The article discusses how to navigate the complex causes of the AMR challenge, and how to foster innovation of new treatments.

 

Collaborative sustainability by all, for all | January 2024
Source: CPHI Online
CPHI Online has released its 2024 Pharma Trends Outlook report, in which Thought Leadership’s Aurelio Arias contributed to an article on sustainability. The article considers how ESG topics will remain important for pharma in 2024, and discusses the volume of carbon emissions from pharma.

 

Nine for 2024, Pt. 1: From fragility to resilience | December 2023
Source: Pharmaphorum
The first of two articles on trends in the pharma and life sciences industries to watch out for in 2024. This part covers how pharma companies and healthcare systems can address issues of fragility by looking at emerging markets, supply chains, and addressing the healthcare capacity gap.

 

Pro Take: Making Medicines Greener | October 2023
Source: WSJ Sustainable Business
Making and supplying medicines generates roughly a third of the global healthcare industry’s greenhouse-gas emissions. Pharmaceutical companies committed to lowering their carbon footprint say the main challenges arise from their scope 3 emissions. The article covers how pharma companies can reduce their emissions from these sources.

 

Microbiome therapeutics could be the next big thing in pharma | June 2023
Source: Healthcare Brew
The microbiome-based therapeutic market is expected to be worth $1.6 billion by 2026. Interest in this field is growing, especially with two drugs targeting the microbiome being approved in the past year. What is the outlook for the microbiome?

 

Nine for 2023, part one: a reflection on inflection | January 2023
Source: Pharmaphorum
The first in a 3-part series on what trends will be affecting the pharma and life sciences industries in the upcoming year. This first part focuses on global healthcare environmental challenges and what they mean for the pharmaceutical industry.

 

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms | January 2023
Source: Pharmaphorum
This second part of the 3-part series focuses on opportunities for pharma; the unmet need which lies at the heart of better healthcare provision, Point of Care Diagnostics and new pharmacotherapy classes becoming commercially available in 2023.

 

Nine for 2023, part three: surviving or thriving? | January 2023
Source: Pharmaphorum
This final part of the 3-part series concerns issues that will change the direction of healthcare and the pharmaceutical industry this year, with three key competitive issues for pharmaceutical companies in 2023 being assessed.

 

3 ways healthcare systems can reduce their carbon footprint | November 2022
Source: World Economic Forum
Rapid climate change has a direct impact on human health. The risk to human health bears down heavily upon healthcare systems. What can be done by these systems to reduce their carbon emissions?

 

“Your order has been dispatched”: Moving patient care closer to the home | October 2022
Source: Medhealth Outlook
Healthcare has increasingly moved towards treating patients at an individual level. As part of this phenomena there is a growing focus on providing patients greater flexibility on the location and timing of how they receive care. Learn how pharma and others can success during this change.

 

Is the launch environment really more competitive now? | October 2022
Source: Pharmaphorum
It’s often stated - mostly without reference to data - that the environment for innovative launches is more competitive now than it ever has been. Is this true? We interrogate this claim using IQVIA’s long term market data to analyse nearly 30 years of launches.

 

How can countries achieve digital maturity in healthcare? | August 2022
Source: World Economic Forum
Healthcare systems are becoming increasingly digitised, but this trend has accelerated in the last 10 years, as well as been given a huge boost by the COVID-19 pandemic. Progression towards digital maturity is uneven between countries, but there are successful examples to follow.

 

How clinical development can tackle Africa's unique health needs | May 2022
Source: World Economic Forum
By 2050, the United Nations projects that 25% of all humanity will be African, with non-communicable diseases poised to become the leading cause of deaths in sub-Saharan Africa. The poor level of commercially led clinical development activity in Africa must be addressed considering these changing factors.

Contact Us